Kilambi News
Sunday, November 22, 2026

Viatris buys Pacira for $1.65 billion to grow pain portfolio

Life Sciences Thursday, October 8, 2026 - Updated Nov 17, 2026 10:24

Viatris completed its acquisition of Pacira BioSciences on November 17, paying $36.50 a share in cash in a tender offer and merger worth about $1.69 billion in aggregate, and Pacira is now a wholly owned Viatris subsidiary.

Why it matters: The closing delivers the non-opioid pain drugs Exparel and Zilretta, which booked $692 million in 2025 sales, into Viatris's portfolio on the timetable set at announcement, with generic pressure on Exparel still the central risk from 2030.

Data as of Updated November 17, 2026: Viatris Form 8-K filed November 17, 2026 (accession 0001140361-26-044356), read in full on EDGAR; all completion figures and terms are the filing's own. Deal announced October 8, 2026 and first reported from BioPharma Dive and Endpoints News.

Latest: Viatris completed the acquisition on Tuesday, November 17. Its tender offer expired one minute after 11:59 p.m. Eastern on November 16 with 32,929,780 Pacira shares validly tendered, about 66.46 percent of the shares outstanding, and Viatris accepted all tendered shares for payment at $36.50 a share in cash. Its acquisition subsidiary then merged into Pacira without a stockholder vote under Delaware law, each remaining share converted into the same $36.50, and Pacira continues as a wholly owned Viatris subsidiary. The aggregate amount to be paid in the offer and the merger is about $1.69 billion, excluding fees and expenses, funded with cash on hand and short-term borrowings, according to Viatris’s Form 8-K filed the same day.

Viatris said it will pay Pacira investors $36.50 per share in cash, a 45 percent premium over Wednesday’s closing price, and expects the deal to close by the end of 2026. Pacira’s two main products, the post-surgical pain drug Exparel and the osteoarthritis knee-therapy Zilretta, are novel formulations of the older non-opioid pain relievers bupivacaine and triamcinolone. The pair booked $692 million in 2025 sales, up about 4 percent, and Viatris said it expects to expand their reach across select markets through its global infrastructure.

Viatris already owns the pain drugs Celebrex and Relpax and could soon launch a fast-acting version of meloxicam if the FDA clears it by a December 27 decision deadline. Leerink analyst Daniel Clark called the transaction “immediately accretive” to revenue and a source of margin expansion into the 2030s, fitting Viatris’s strategy of buying on-market commercial assets. Clark added that while the near-term trajectory likely does not change meaningfully, the deal is “steady sources of growth” execution against its capital deployment strategy.

The risk is generic erosion. Patent settlements Pacira struck last year with Fresenius Kabi and a Hengrui Pharma subsidiary allow the two companies to begin marketing small shares of total U.S. Exparel volume as early as 2030, escalating to around 30 percent within three years. Manufacturing patents won in 2024 push Exparel’s intellectual property protections to 2044 according to the FDA’s Orange Book, but two other manufacturers are challenging those patents. Zilretta’s patents expire in 2031. Viatris said it plans to leverage its intellectual property expertise to extend product lifecycles after generics arrive, which is the central bet of the transaction.

Sources

  1. Viatris boosts pain drug portfolio with $1.7B buyout of Pacira - BioPharma Dive - 2026-10-08
  2. Viatris Inc., Form 8-K (completion of Pacira merger, accession 0001140361-26-044356) - US Securities and Exchange Commission, EDGAR - 2026-11-17
  3. Viatris to make $1.65B Pacira acquisition, adding to momentum in pain - Endpoints News - 2026-10-08